In order to meet the needs of pharma and biotech companies ERGOMED has developed a flexible shared risk approach to drug development. By sharing the risk and expense of development with the sponsors, this model has been used effectively to enable drugs to be developed more quickly and more comprehensively to proof of concept. By applying the additional Ergomed support companies are able to either initiate additional clinical trials that would otherwise be beyond the current budget or add further resource to existing programmes to complete clinical trials.Partners view this offering as a useful alternative in managing their portfolio.
ERGOMED is interested in participating in co-development partnerships in circumstances where the needs of the biotech or pharma partner are met by the expertise in clinical strategy, therapeutic area and full service clinical operations that comprise ERGOMED’s contribution to the project.
ERGOMED offers practical assistance in managing all aspects of clinical development programmes from phases I to registration trials through the associated corporate and regulatory milestones. For all these essential tasks within clinical product development ERGOMED has an experienced team that is taliored specifically for each product/ partnership to offer a targeted and personal approach.